MedTrace Logo

Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer

NCT04124601 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-04-23

No results posted yet for this study

Summary

This prospective randomized, open-label, multicenter, phase II clinical trial investigates the safety and tolerability of standard neoadjuvant chemoradiotherapy (CRT) with sequential ipilimumab and nivolumab in rectal cancer.

Conditions

Interventions

RADIATION

Chemoradiotherapy

Capecitabine tablet with fractionated radiotherapy

DRUG

Ipilimumab

Infusion

DRUG

Nivolumab

Infusion

Sponsors & Collaborators

Principal Investigators

  • Michael Bergmann, MD · Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2024-03-15
Completion
2024-03-15
FDA Drug
Yes

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04124601 on ClinicalTrials.gov